Healthcare / BiotechnologyASX
$0.18
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.0M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$111M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-99.0%
↓Gross Margin
100.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
698.6%
FCF / Net income
-2.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.6M · net income $-13.3M · FCF $39.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.6M | $5.6M | $407466.00 | — | — |
| Net Income | $-13.3M | $-13.3M | $-17.1M | $-13.8M | $-10.5M |
| EBITDA | $-31.9M | $-31.9M | $-25.2M | $-22.8M | $-16.9M |
| EPS | -0.02 | -0.02 | -0.04 | -0.04 | -0.03 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -572.9% | -572.9% | -6193.4% | — | — |
| Net Margin | -237.2% | -237.2% | -4190.6% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 1.00 | 0.01 |
| Current Ratio | 3.15 | 3.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $39.0M | $39.0M | $-7.0M | $-12.7M | $-13.4M |
| Returns | |||||
| ROE | -99.0% | -99.0% | -93.9% | -231.5% | -72.7% |
| Valuation | |||||
| P/B | 7.75 | 7.75 | 11.33 | 4.15 | 2.86 |
| Growth & Yield | |||||
| Revenue Growth | 1271.1% | 1271.1% | — | — | — |
| EPS Growth | 37.4% | 37.4% | 11.1% | -21.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-67.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.02
Residual
-67.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.